Protagonist Therapeutics, Inc. (PTGX)

Add to research

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Company performance
Add to research
View more

Current Price

as of Apr 25, 2025

$44.49

P/E Ratio

10.50

Market Cap

$2.72B

Description
Add to research
View more

Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

Metrics
Add to research
View more

Overview

  • HQNewark, CA
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerPTGX
  • Price$44.49-0.80%

Trading Information

  • Market cap$2.72B
  • Float94.29%
  • Average Daily Volume (1m)1,285,835
  • Average Daily Volume (3m)1,199,792
  • EPS$4.47

Company

  • Revenue$434.43M
  • Rev growth (1yr)624.06%
  • Net income$275.19M
  • Gross margin99.32%
  • EBITDA margin58.88%
  • EBITDA$255.81M
  • EV$2.10B
  • EV/Revenue4.84
  • P/E10.50
  • P/S6.65
  • P/B4.01
  • Debt/Equity1.61
Documents
Add to research
View more
SEC Filings
8-K (2025-03-20)
8-K (2025-03-10)
8-K (2025-03-03)
8-K (2025-02-21)
8-K (2025-01-06)
8-K (2024-11-18)
8-K (2024-11-07)
8-K (2024-09-20)
8-K (2024-08-06)
8-K (2024-06-26)
8-K (2024-05-07)
8-K (2024-02-27)
8-K (2024-01-31)
8-K (2024-01-16)
8-K (2024-01-08)
8-K (2023-11-02)
8-K (2023-10-30)
8-K (2023-08-03)
8-K (2023-07-05)
8-K (2023-07-03)
8-K (2023-05-30)
8-K (2023-05-04)
8-K (2023-04-10)
8-K (2023-03-15)
8-K (2023-03-10)
8-K (2023-01-06)
10-Q (2024-11-07)
10-Q (2024-08-06)
10-Q (2024-05-07)
10-Q (2023-11-02)
10-Q (2023-08-03)
10-Q (2023-05-04)
10-K (2025-02-21)
10-K (2024-02-27)
10-K (2023-03-15)
Earnings Calls
Earnings Report 2020Q4
Earnings Report (2021-03-10)
Factset Street Account
Protagonist Therapeutics reports Q3 EPS ($0.58) vs FactSet ($0.69) [6 est, ($0.76)-(0.67)] ($15.41, 0.00) (2023-11-03T18:16:47Z)
Protagonist Therapeutics initiated overweight at Capital One Securities ($14.08, 0.00) (2023-10-30T10:34:03Z)
Protagonist Therapeutics holder Point72 discloses 5.5% passive stake - 13G ($20.73, 0.00) (2023-12-18T21:20:36Z)
Protagonist Therapeutics announces advancement of JNJ-2113 across multiple indications ($16.24, 0.00) (2023-10-09T11:04:14Z)
Protagonist Therapeutics acheives $50M milestone after third patient dosed in phase 3 study of JNJ-2113 in moderate-to-severe psoriasis ($15.11, 0.00) (2023-11-01T20:43:31Z)
Protagonist announces two new phase 3 ICONIC studies in psoriasis evaluating JNJ-2113 in head-to-head comparisons with deucravacitinib ($17.23, 0.00) (2023-11-27T14:09:07Z)